Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TTRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $247.49M
- EPS (TTM)
- -$0.43
- Dividend yield
- None
- 52-week range
- 2.70 – 16.45
- Day range
- 7.93 – 9.20
- Volume / Avg
- 82.67K / 119.32K
- Beta
- —
- Shares outstanding
- 30.57M
52-week range
TTRX stock today
On Nov 20, TTRX ended the session at $8.10, shedding $0.545 (6.31%), versus the S&P 500's 3.70% decline. At this level, TTRX sits in the middle of its 52-week range of $2.70 to $16.45: 50.8% below the high, set on Sep 18, 2026 and 199.8% above the low. TTRX is up 105.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 147.6%.
Turn Therapeutics has posted a net loss over the last twelve months (EPS of -$0.43), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Turn Therapeutics
Company profileTurn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Bradley E. Burnam
- Headquarters
- Westlake Village, CA
- Employees
- 2
- Website
- turntherapeutics.com
Financial highlights
Full financialsTurn Therapeutics reported a net loss of $3.2 million, compared with a loss of $1.8 million a year earlier. Diluted earnings per share came in at -$0.12.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-3.19M | $-1.77M |
| EPS (diluted) | $-0.12 | $-0.07 |
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$25.00+208.83%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.21 vs —
TTRX news
All TTRX newsTurn Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs TTRX |
| LFCRLifecore Biomedical Inc. | 6.39 | +0.31% | $242.22M | vs TTRX |
| CAMPCAMP4 Therapeutics Corporation | 3.79 | -5.25% | $237.84M | vs TTRX |
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs TTRX |
| ALTAltimmune Inc. | 1.33 | -5.67% | $258.80M | vs TTRX |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs TTRX |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs TTRX |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs TTRX |
Indexes, lists and sector
Turn Therapeutics stock FAQ
What is Turn Therapeutics's stock price today?
TTRX last traded at $8.10 as of Nov 20, 4:00 PM EST, down 6.31% on the day. Prices are delayed at least 15 minutes.
Who is Turn Therapeutics's CEO?
Mr. Bradley E. Burnam is the chief executive officer of Turn Therapeutics Inc., which has about 2 employees.
What is the TTRX 52-week high?
The 52-week high for TTRX is $16.45 and the 52-week low is $2.70. The stock is currently 50.8% below its high.